Show simple item record

dc.contributor.authorHideshima, Teru
dc.contributor.authorRaje, Noopur
dc.contributor.authorRichardson, Paul Gerard Guy
dc.contributor.authorAnderson, Kenneth Carl
dc.date.accessioned2010-12-08T18:23:07Z
dc.date.issued2008
dc.identifier.citationHideshima, Teru, Noopur Raje, Paul G. Richardson, and Kenneth C. Anderson. 2008. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Therapeutics and Clinical Risk Management 4(1): 129-136.en_US
dc.identifier.issn1176-6336en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:4621017
dc.description.abstractLenalidomide (also known as Revlimid®, CC-5013) is an immunomodulatory derivative of thalidomide and has more potent anti-tumor and anti-inflammatory effects than thalidomide. The molecular mechanisms of anti-tumor activity of lenalidomide have been extensively studied in multiple myeloma (MM) both preclinical models and in clinical trials. Lenalidomide: directly triggers growth arrest and/or apoptosis of drug resistant MM cells; inhibits binding of MM cells to bone marrow (BM) extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the BM milieu; and augments host anti-tumor immunity. Lenalidomide achieved responses in patients with relapsed refractory MM. Moreover, lenalidomide with dexamethasone (Dex) demonstrates more potent anti-MM activities than Dex both in vitro and in randomized phase III clinical trials. Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy.en_US
dc.language.isoen_USen_US
dc.publisherDove Medical Pressen_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503648/pdf/en_US
dash.licenseLAA
dc.subjectlenalidomideen_US
dc.subjectdexamethasoneen_US
dc.subjectmultiple myelomaen_US
dc.titleA Review of Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myelomaen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalTherapeutics and Clinical Risk Managementen_US
dash.depositing.authorHideshima, Teru
dc.date.available2010-12-08T18:23:07Z
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dash.affiliation.otherHMS^Medicine-Massachusetts General Hospitalen_US
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dash.affiliation.otherHMS^Medicine-Brigham and Women's Hospitalen_US
dash.contributor.affiliatedRaje, Noopur
dash.contributor.affiliatedHideshima, Teru
dash.contributor.affiliatedRichardson, Paul
dash.contributor.affiliatedAnderson, Kenneth


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record